Variant Perception

Where We Disagree With the Market

The market is pricing Elevance Health as a routine cyclical-trough managed-care insurer with one large but contained regulatory accrual ($935M for historical Medicare Advantage risk-adjustment data) and a clear path back to 12%+ EPS growth in 2027. We disagree with three specific assumptions inside that consensus. First, the $935M accrual is being treated as the cap on Medicare Advantage coding exposure, but the January 14, 2026 Kaiser Permanente settlement ($556M for 2009-2018 conduct) and the active DOJ False Claims Act case against Anthem (fact discovery closes June 30, 2026) point to a parallel, separately-reservable liability that the trailing multiple does not contemplate. Second, the Q1 FY2026 operating margin of 3.99% is being read as trough confirmation, but Q1 is structurally ELV's strongest seasonal quarter — Q1 prints of 6.86% (FY2024) and 6.18% (FY2025) collapsed to full-year results of 4.16% and 3.33% respectively, so a 3.99% Q1 likely implies a full-year FY2026 operating margin BELOW the FY2025 trough, not above it. Third, the consensus FCF-recovery assumption embedded in the 13.9x P/E (and the implicit FCF/share that justifies the buyback pace) ignores that receivables doubled from $11B to $21.5B over five years; that working-capital absorption is structural, not cyclical, and even mid-cycle FCF/NI is unlikely to return to the 2020-2023 average of 1.3x.

The cleanest resolution sits inside a 90-day window: the CMS RADV compliance deadline (July 31, 2026), Q2 FY2026 earnings (~late July 2026), and the close of DOJ-Anthem fact discovery (June 30, 2026) are all stacked. None of these require us to be smarter than the market — only to read the same data points more skeptically.

Variant Perception Scorecard

The 68/100 variant strength reflects a debate that is unusually well-defined: each of three disagreements maps to a dated, observable signal inside three months, the consensus position is documented across analyst PT moves and Q1 commentary, and the evidence base is a published Kaiser settlement plus 16 quarters of ELV's own segment data. The score is held below 80 because (a) the Kaiser-precedent argument requires the DOJ-Anthem case to settle rather than litigate to verdict, and (b) the seasonal-margin argument can be invalidated by a single Q2 print above 4%. Both are testable inside the next two earnings cycles.

Consensus Map

What the market appears to believe, and how we know.

Three of these consensus reads (regulatory cap, cycle position, cash conversion) are where our evidence pushes back. The other three (Carelon premium, insider signal, Star Ratings) are where consensus is reasonable; we do not disagree for the sake of disagreement.

The Disagreement Ledger

Three ranked variant views, each paired with a specific resolution signal.

#1 — RADV is not the regulatory cap

A consensus analyst would say the $935M accrual is conservatively sized at the midpoint of a -$585M / +$565M disclosed range, that management has explicitly framed CMS RADV as a process item rather than an admission of liability, and that the broader FCA backdrop is industry-wide (UnitedHealth, Anthem, Kaiser all named) rather than ELV-specific. Our evidence pushes back on the framing rather than the accrual size: the $556M Kaiser FCA settlement landed January 14, 2026 as the largest-ever MA risk-adjustment resolution, and the parallel DOJ-Anthem chart-review case is in active fact discovery closing June 30, 2026 with no public reserve disclosed (per Mintz EnforceMintz tracker, January 20, 2026). If the bull is right, the market would have to concede the $935M is the CMS-side resubmission cost and the FCA exposure is a separate accrual that has not yet been booked. The cleanest disconfirming signal is a clean July 31, 2026 CMS attestation acceptance combined with a June/July 8-K explicitly addressing DOJ-Anthem reserve adequacy; absence of either keeps the disagreement intact.

#2 — Q1 is the seasonal peak, not the cycle trough

A consensus analyst would say the Q1 2026 op margin of 3.99% is a 370 bp sequential rebound from Q4 2025's 0.29%, that management raised the FY2026 EPS floor on the print, and that the historical pattern after the 2008-09 and 2017 cycles was a recovery to 5%+ within 24 months once the first up-quarter printed. Our disagreement is more arithmetic than analytical: Q1 has been ELV's seasonally strongest quarter in three of the last three years, and Q1 FY2026's 3.99% print is the LOWEST Q1 in at least eight years, not a confirmation of a new run-rate. Q1 2024's 6.86% became a full-year 4.16%; Q1 2025's 6.18% became a full-year 3.33%; the same seasonal compression on a Q1 of 3.99% lands the full year somewhere between 2.5% and 3.0% — a SECOND consecutive year below 4%, not a recovery. If the market is right, Q2 would print at or above 4% with the benefit-expense ratio under 88%, breaking the 2024 and 2025 pattern; if our reading is right, Q2 drifts toward 3-3.5% with MLR at 87.5-88%, and the FY2026 raised guide of $26.75 is at risk by Q3.

#3 — Cash conversion has structurally reset

A consensus analyst would say the FY2025 CFO of $4.3B (CFO/NI 0.76x) is a known cyclical headwind, that management has explicitly committed to $5.5B+ of CFO in FY2026, and that the receivables build is the natural counterpart of premium growth and Medicaid acuity churn that will reverse as the cycle normalizes. Our disagreement is that the $10.6B receivables build (FY2020 to FY2025) is not the typical year-over-year working-capital noise — it is a five-year structural increase across two regulatory regimes, an Anthem-to-Elevance rebrand, and three large acquisitions (BioPlus, Paragon, CareBridge), and the days-payable-outstanding moved the wrong way (18d → 15d) over the same period. If the market is right, FY2026 CFO comes in at $5.5B+ and FCF/NI returns above 0.9x by Q4; if we are right, FY2026 CFO falls short of guide and the buyback authorization either slows or gets debt-funded again. The cleanest test is FY2026 CFO disclosure paired with year-end days-in-claims-payable; a return to 41-42d on DCP combined with $5.5B+ CFO breaks our view.

Evidence That Changes the Odds

The seven evidence items below are the ones that move the variant probability up or down — not the comprehensive bear case.

The Kaiser precedent (Evidence #1) and the DOJ-Anthem discovery timing (Evidence #2) carry the most weight because they are external, dated, and not contingent on management commentary. The seasonality argument (Evidence #3) is arithmetically compact but a single Q2 print can break it. The cash-conversion structural-reset case (Evidence #5) is the slowest-resolving but the most material to long-run fair value if it holds.

Quarterly Operating Margin — Q1 Has Been the Seasonal Peak

The chart below is the empirical core of variant view #2. Each Q1 since FY2023 has been the calendar year's strongest quarter, and Q1 FY2026 prints below all three prior Q1s.

The three-year average gap between Q1 op margin and the full-year result is -2.43pp. Applying that gap to Q1 FY2026 implies a full-year op margin of approximately 1.6%, which is unrealistically low given the Q1 print already includes the worst Q4 reset (FY2025 Q4 at 0.29%). A more conservative gap assumption of -1.14pp (better than any prior year because Medicaid rate catch-up improves Q4) implies a full-year FY2026 op margin near 2.85%, BELOW the FY2025 reset of 3.33%. Either way, the bull-case framing of "trough confirmed" requires the seasonal pattern to break in 2026 — possible, but the burden of proof sits with consensus.

How This Gets Resolved

Six observable signals in the next 90-180 days. Each maps to a specific filing or disclosure.

Three of the six signals (#1, #2, #3) resolve inside 90 days. Two of those three (#1 and #3) are external — driven by CMS and DOJ rather than ELV's own commentary — which makes the variant view unusually testable for a managed-care insurer.

What Would Make Us Wrong

The cleanest path to invalidating this variant view runs through three observable events, each of which we are watching for.

The Kaiser precedent could turn out to be Kaiser-specific. Kaiser's $556M settlement included a 2x FCA multiplier on $278M of restitution — a standard structure. But Kaiser's MA business is integrated with its own provider network, which made the chart-review and addenda allegations more provable. ELV operates a more conventional payer model, which means the DOJ-Anthem case has a harder evidentiary path. The UnitedHealth Special Master Report and Recommendation in March 2025 concluded that the government had failed to establish "overpayments" or "materiality" on the same reverse-false-claims theory. If the trial judge in the United case adopts that R&R (decision pending after a November 2025 hearing) AND the DOJ-Anthem judge follows the same logic, ELV could achieve summary judgment and avoid trial — potentially without a settlement reserve. If both happen, variant view #1 collapses and the $935M genuinely is the cap.

The seasonality argument can break with one Q2 print. If Q2 FY2026 op margin lands at 4.0%+ with the benefit expense ratio at 87% or below, the prior-three-years seasonal pattern of Q1 → Q4 compression is violated and the trough-confirmation framing is correct. The bull case is correct that Medicaid rate catch-up flowing into 2026 contracts is structurally different from the 2024 and 2025 trend misses; if rates have caught up, Q2 should not seasonally compress the way it did in those years. The variant view leans on the assumption that the same pattern repeats — a strong base rate, but not a certainty.

The cash-conversion reset could be receivables timing, not structural. A meaningful portion of the $10.6B receivables build over five years is associated with Medicare Advantage prospective payments, Medicaid rate true-ups, and ACA risk-adjustment receivables that genuinely reverse as cycles normalize. If FY2026 CFO comes in at $5.5B+ with a clear schedule showing receivables stabilizing, the structural-reset framing is wrong and the bull-case FCF math holds. We are watching for the FY2026 receivables-to-revenue ratio (currently 10.9% vs. 9.1% in FY2020) to revert toward the pre-2024 baseline.

A final caveat on humility: the bear case at ELV has been right about cash conversion and adjusted-EPS quality for 18 months and the stock has nevertheless made back ~30% from its mid-2025 lows. The variant view has to clear not just the analytical bar but the implementation bar — which for a stock with $514M of average daily volume is unusually generous. That said, three of the six resolution signals land inside 90 days, and one of them (CMS July 31) is a hard external date. The variant view is testable; the only question is whether the test resolves the way the evidence suggests.

The first thing to watch is the July 31, 2026 CMS RADV compliance disclosure paired with any new legal-contingency footnote in the Q2 FY2026 10-Q.